Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study will assess short term safety, antiviral activity and pharmacokinetics (PK) of
IDX184 in combination with Peg-interferon (Peg-IFN)/Ribavirin (RBV) in participants with
hepatitis C virus (HCV) genotype (GT) 1 infection. These data will guide dose selection for
future, longer term studies.